A SPLUNC1-derived anti-biofilm peptide encapsulated in PLGA-chitosan nanoparticles achieved 61% biofilm reduction, >92% cell viability, and aerodynamic properties suitable for deep lung delivery.
Inhaled peptide therapyNanoparticle-encapsulated lung defense peptide achieves deep lung delivery with sustained 72-hour release and 61% biofilm disruption
What the researchers found
KQ peptide in PLGA-chitosan NPs: 60.99% biofilm reduction, >92% cell viability in A549 cells, <1% hemolysis, 150-350 nm size, sustained release 72h, aerodynamic diameter ≤5 μm for deep lung delivery.
Why it matters
Chronic lung infections with biofilm-forming S. aureus are extremely difficult to treat. An inhaled peptide therapy that disrupts biofilms could transform management of conditions like cystic fibrosis lung infections.
How the study worked
Rational peptide design from SPLUNC1, PLGA and PLGA-chitosan nanoparticle formulation, characterization (size, zeta potential, SEM/TEM, encapsulation, release), anti-biofilm assays, cytotoxicity (A549), hemolysis, and NGI aerodynamic assessment.
What this study cannot tell us
In vitro only. In vivo lung infection models needed. Manufacturing scalability of peptide-loaded nanocomposites uncertain.
How to read the evidence
In vitro formulation study with aerodynamic characterization. Promising platform needing in vivo validation.
When this study was published
Published in 2025.
The bigger picture
Combining lung-derived antimicrobial peptides with inhaled nanoparticle delivery creates a biomimetic approach that leverages the body's own defense molecules.
Questions still open
- Would inhaled KQ-NPs reduce S. aureus biofilm in an animal lung infection model?
- Could this approach work for other biofilm-forming pathogens like P. aeruginosa?
- How does the nanoparticle stability hold up in stored inhaler devices?
Common questions
How does an inhaled peptide fight lung infections?
Why use nanoparticles?
Read the original research
Lung SPLUNC1-derived anti-biofilm peptide in polymeric nanoparticles: A novel strategy against S. aureus biofilms and antimicrobial resistance.
International journal of biological macromolecules, 339(Pt 2), 149552
Citation
Gaur, Manish; Maurya, Sarita; Tripathi, Ritu; Pasupuleti, Mukesh; Akhtar, Md Sohail; Swaroop, Shiv; Yadav, Awadh Bihari. (2026). Lung SPLUNC1-derived anti-biofilm peptide in polymeric nanoparticles: A novel strategy against S. aureus biofilms and antimicrobial resistance.. International journal of biological macromolecules, 339(Pt 2), 149552. https://doi.org/10.1016/j.ijbiomac.2025.149552